GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early trading,
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted fourth-quarter profit ahead of analyst expectations.
GSK lifts long-term sales targets on new drug pipeline
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.
GSK intends to commence GBP 2B share buyback program
Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.
The GSK share price jumps 6% on positive FY 2024 results. Is it a stock to consider now?
Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.
GSK Announces £2 Billion Share Buyback as Profit Beats Estimates
GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...
Miners drive robust FTSE 100, Future shares higher on US progress
GSK’s 6% results-day share price advance is the standout performance in an otherwise subdued FTSE 100 index. Miner Fresnillo ...
GSK sees FY25 core EPS growth 6%-8%
GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
bovnews17h
GSK’s Unexpected Plunge: What’s Next?
On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...
Earnings dominate sentiment, as GSK shines, and Google dives
As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...
GSK falls Tuesday, underperforms market
GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.